Initial Clinico-Biological Characteristics and Follow-up Data of Elderly Patients With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of a Series of 364 Cases

被引：1
|
作者：
Baumann, Tycho [1 ,2 ]
Delgado, Julio [1 ]
Santacruz, Rodrigo [1 ]
Martinez-Trillos, Alejandra [1 ,2 ]
Royo, Cristina [2 ]
Navarro, Alba [2 ]
Pinyol, Magda [2 ]
Rozman, Maria [2 ]
Villamor, Neus [2 ]
Aymerich, Marta [2 ]
Carrio, Anna [2 ]
Montserrat, Emil [1 ]
机构：
[1] Univ Barcelona, Inst Hematol & Oncol, Dept Hematol, Hosp Clin,Inst Invest Biomed August Pi & Sunyer I, Barcelona, Spain
[2] Univ Barcelona, Hematopathol Unit, Dept Pathol, Hosp Clin,IDIBAPS, Barcelona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2014年 / 14卷
关键词：
D O I：
10.1016/j.clml.2014.06.056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
301
引用
收藏
页码：S129 / S130
页数：2
相关论文
共 50 条
  • [31] Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Brander, Danielle M.
    Tyekucheva, Svitlana
    Chen, Chinheng
    Kaminski, James
    Montegaard, Josie
    Alencar, Alvaro J.
    Alencar, Alvaro J.
    Omaira, Mohammad
    Jacobson, Caron
    Armand, Philippe
    Ng, Samuel Y.
    Crombie, Jennifer L.
    LaCasce, Ann S.
    Arnason, Jon E.
    Hochberg, Ephraim
    Takvorian, Ronald W.
    Abramson, Jeremy S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2021, 138
  • [32] GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT
    Montesinos, Pau
    Lopez-Corral, Lucia
    Valcarcel, David
    Rovira, Montserrat
    Antonio Garcia-Marco, Jose
    Loscertales, Javier
    Moreno, Carol
    Duarte, Rafael
    Jose Terol, Maria
    Abrisqueta, Pau
    Cabrero, Monica
    Sanz, Jaime
    Delgado, Julio
    BONE MARROW TRANSPLANTATION, 2018, 53 : 244 - 245
  • [33] Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.
    Offner, Fritz
    Robak, Tadeusz
    Janssens, Ann
    Kanakasetty, Govind Babu
    Kloczko, Janusz
    Grosicki, Sebastian
    Mayer, Jiri
    Panagiotidis, Panagiotis
    Schuh, Anna
    Pettitt, Andrew
    Montillo, Marco
    Werner, Olena
    Vincent, Ghislaine
    Khanna, Sadhvi
    Hillmen, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Detailed long-term follow-up of treatment-nayve chronic lymphocytic leukemia (CLL) patients in the Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial; data on 17 (15% of total cohort) patients from a single-institution
    Sandhu, Suneet
    Mackinlay, Naomi
    Coyle, Luke
    Best, Giles
    Mulligan, Stephen
    LEUKEMIA & LYMPHOMA, 2015, 56 : 29 - 31
  • [35] COMBINATED ANTIBODY DEFICIENCY AND INFECTIOUS FREE SURVIVAL IN HYPOGAMMAGLOBULINEMIA PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A LONG TERM FOLLOW UP MONOCENTRIC REAL-LIFE COHORT ANALYSIS
    Murru, R.
    Caocci, G.
    Galitzia, A.
    Uda, S.
    Culurgioni, F.
    Oppi, S.
    La Nasa, G.
    HAEMATOLOGICA, 2019, 104 : 100 - 101
  • [36] Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission-long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
    Schweighofer, C.
    Ritgen, M.
    Eichhorst, B.
    Busch, R.
    Kneba, M.
    Hallek, M.
    Wendtner, Clemens
    BLOOD, 2006, 108 (11) : 14A - 14A
  • [37] Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution
    Sandhu, Suneet
    Mackinlay, Naomi
    Coyle, Luke
    Best, Giles
    Mulligan, Stephen
    BLOOD, 2015, 126 (23)
  • [38] Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study
    Greil, Richard
    Fraser, Graeme
    Leber, Brian
    Marks, Reinhard
    Quaresmini, Giulia
    Middeke, Jan Moritz
    Semenzato, Gianpietro
    Schary, William
    Boyer, Michelle
    Breuleux, Madlaina
    Crompton, Noelle
    Humphrey, Kathryn
    Marlton, Paula
    BLOOD, 2018, 132
  • [39] Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a 4-year follow-up from the RESONATE-2 study
    Burger, J. A.
    Barr, P. M.
    Robak, T.
    Owen, C.
    Ghia, P.
    Tedeschi, A.
    Bairey, O.
    Hillmen, P.
    Coutre, S. E.
    Devereux, S.
    Grosicki, S.
    McCarthy, H.
    Li, J.
    Simpson, D.
    Offner, F.
    Moreno, C.
    Dai, S.
    Dean, J. P.
    James, D. F.
    Kipps, T. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 29 - 29
  • [40] Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)
    Burger, Jan A.
    Robak, Tadeusz
    Demirkan, Fatih
    Bairey, Osnat
    Moreno, Carol
    Simpson, David
    Munir, Talha
    Stevens, Don A.
    Dai, Sandra
    Cheung, Leo W. K.
    Kwei, Kevin
    Lal, Indu
    Hsu, Emily
    Kipps, Thomas J.
    Tedeschi, Alessandra
    BLOOD, 2020, 136
12345